Company / Operating Cash Flow
TEVA PHARMACEUTICAL INDUSTRIES LTD Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$1.6B
FY2025
5-year range
$798.0M / $1.6B
FY2021-FY2025
Trend
+32.2%
vs FY2024
Sector context
#16 of 216
Health Care
What the data says
Among 216 Health Care companies, TEVA PHARMACEUTICAL INDUSTRIES LTD is in the top 7% for operating cash flow. Operating Cash Flow returned to growth in FY2025 after 2 years of decline, reaching $1.6B.
Based on SEC 10-K filings.
$1.6B in FY2025 with a 5-year CAGR of +6.3%. Top quartile in the Health Care sector.
Improved from $1.4B to $1.6B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +1.2%
- 5-Year CAGR
- +6.3%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 216This company $1.6B Sector average $659.0M
▼
+150.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +6.3%, indicating consistent growth.
- In FY2025, operating cash flow increased 32.2% year-over-year.
- Ranks #16 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6B | +32.2% |
| FY2024 | $1.2B | -8.8% |
| FY2023 | $1.4B | -14.0% |
| FY2022 | $1.6B | +99.2% |
| FY2021 | $798.0M | -34.4% |
| FY2020 | $1.2B | +62.6% |
| FY2019 | $748.0M | -69.4% |
| FY2018 | $2.4B | +9.9% |
| FY2017 | $2.2B | -42.8% |
| FY2016 | $3.9B | -29.8% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026